Literature DB >> 21106031

Clinical predictors of exacerbation frequency in chronic obstructive pulmonary disease.

Marjolein Brusse-Keizer1, Job van der Palen, Paul van der Valk, Ron Hendrix, Huib Kerstjens.   

Abstract

INTRODUCTION: Reduction of exacerbation frequency plays an increasingly important role in interventions in chronic obstructive pulmonary disease (COPD). To reduce this frequency efficiently, patients at risk for frequent exacerbations need to be identified.
OBJECTIVE: The objective of the study was to identify predictors for frequent exacerbations from multiple domains of COPD during a stable phase of the disease.
METHODS: Data of multiple domains of COPD were collected from 121 patients with moderate to severe COPD. Patients were divided into infrequent (<2 exacerbations per year) and frequent (≥2 exacerbations) exacerbators.
RESULTS: St. George's Respiratory Questionnaire (SGRQ) total score and a course of oral corticosteroid within 3 months prior to the study together predicted best whether patients would be infrequent or frequent exacerbators over the course of the next year. Each unit increase in total SGRQ score was associated with a 3% higher risk of being a frequent exacerbator [odds ratio (OR) = 1.03; 95% confidence interval (CI): 1.00-1.06; P = 0.047]. Patients who received a course of oral corticosteroids in the period of 3 months prior to the study had a three-fold increased risk of being a frequent exacerbator (OR = 3.17; 95% CI: 1.20-8.34; P = 0.02). Furthermore, we observed that a sizable number of patients switched from being a frequent to an infrequent exacerbator and vice versa.
CONCLUSIONS: Health-related quality of life and a course of oral corticosteroid in the past 3 months are the best predictors of future exacerbator status. The predictive value of the model is, however, still insufficient. Furthermore, our data suggest, in contrast to previous observations, that exacerbation frequency is not a constant feature.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106031     DOI: 10.1111/j.1752-699X.2010.00234.x

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  7 in total

Review 1.  Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.

Authors:  Alvar Agustí; Peter M Calverley; Marc Decramer; Robert A Stockley; Jadwiga A Wedzicha
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

2.  Predicting Hospitalization Due to COPD Exacerbations in Swedish Primary Care Patients Using Machine Learning - Based on the ARCTIC Study.

Authors:  Björn Ställberg; Karin Lisspers; Kjell Larsson; Christer Janson; Mario Müller; Mateusz Łuczko; Bine Kjøller Bjerregaard; Gerald Bacher; Björn Holzhauer; Pankaj Goyal; Gunnar Johansson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-16

3.  Predictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study.

Authors:  Gunnar R Husebø; Per S Bakke; Marianne Aanerud; Jon A Hardie; Thor Ueland; Rune Grønseth; Louise J P Persson; Pål Aukrust; Tomas M Eagan
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

4.  Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.

Authors:  MeiLan K Han; Pedro M Quibrera; Elizabeth E Carretta; R Graham Barr; Eugene R Bleecker; Russell P Bowler; Christopher B Cooper; Alejandro Comellas; David J Couper; Jeffrey L Curtis; Gerard Criner; Mark T Dransfield; Nadia N Hansel; Eric A Hoffman; Richard E Kanner; Jerry A Krishnan; Carlos H Martinez; Cheryl B Pirozzi; Wanda K O'Neal; Stephen Rennard; Donald P Tashkin; Jadwiga A Wedzicha; Prescott Woodruff; Robert Paine; Fernando J Martinez
Journal:  Lancet Respir Med       Date:  2017-06-28       Impact factor: 30.700

5.  Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study.

Authors:  Swati Gulati; J Michael Wells; Gisel P Urdaneta; Kira Balestrini; Isabel Vital; Katherine Tovar; Jarrod W Barnes; Surya P Bhatt; Michael Campos; Stefanie Krick
Journal:  Int J Mol Sci       Date:  2019-05-09       Impact factor: 5.923

6.  Genetic variants in IL17A and serum levels of IL-17A are associated with COPD related to tobacco smoking and biomass burning.

Authors:  Marco A Ponce-Gallegos; Gloria Pérez-Rubio; Enrique Ambrocio-Ortiz; Neftali Partida-Zavala; Rafael Hernández-Zenteno; Fernando Flores-Trujillo; Leonor García-Gómez; Andrea Hernández-Pérez; Alejandra Ramírez-Venegas; Ramcés Falfán-Valencia
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

7.  Haplotype in SERPINA1 (AAT) Is Associated with Reduced Risk for COPD in a Mexican Mestizo Population.

Authors:  Marco Antonio Ponce-Gallegos; Gloria Pérez-Rubio; Adriana García-Carmona; Jesús García-Gómez; Rafael Hernández-Zenteno; Alejandra Ramírez-Venegas; Ramcés Falfán-Valencia
Journal:  Int J Mol Sci       Date:  2019-12-27       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.